NEWS RELEASE Web Site Release July 15, 2014 Toronto, ON – today Defyrus announced an exclusive, worldwide license to their Ebola therapeutic monoclonal antibody (mAb) patent portfolio to Leaf Biopharmaceutical Inc. of San Diego, CA. This license expands the commercial relationship between LeafBio and Defyrus who have been actively collaborating
Contact: Caree Vander Linden (301) 619-2285 Fort Detrick, Maryland Caree.VanderLinden@us.army.mil EMBARGOED FOR RELEASE: August 21, 2013 – 2:00 PM Eastern Time Experimental Ebola Treatment Protects Some Primates Even After Disease Symptoms Appear Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies. In this week’s online edition of the Proceedings of the National Academy of Sciences (PNAS), the research team describes a proof-of-concept for using a “cocktail”